drugset / Trial / NCT03978559
Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, randomized clinical trial. During the study, non-HIV patients who are admitted to ICU due to Pneumocystic pneumonia (PCP) and have not received anti-PCP therapy or have received therapy less than 48hrs will be randomized (1:1) to received caspofungin combined with trimethoprim-sulfamethoxazole or trimethoprim-sulfamethoxazole alone. The aim of this study is to compare the effectiveness of caspofungin combined with trimethoprim-sulfamethoxazole with that of conventional therapy (trimethoprim-sulfamethoxazole alone) as first-line therapy in the treatment of severe Pneumocystis pneumonia (PCP) in non-HIV patients.
Timeline
- Start
- 2019-08-14
- Primary completion
- 2022-06-20
- Completion
- 2022-07-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caspofungin | Other / unclassified | 50 mg | Intravenous |
| Subject | Sulfisoxazole | Small molecule | 75 mg/kg | — |
| Subject | Trimethoprim | Small molecule | 15 mg/kg | — |
| Background | Methylprednisolone | Other / unclassified | 20 mg | Intravenous |